These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33395331)

  • 21. Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection.
    Panagopoulos P; Petrakis V; Panopoulou M; Trypsianis G; Penlioglou T; Pnevmatikos I; Papazoglou D
    J Chemother; 2021 May; 33(3):193-197. PubMed ID: 32530369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
    Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.
    Baghaei P; Dastan F; Marjani M; Moniri A; Abtahian Z; Ghadimi S; Valizadeh M; Heshmatnia J; Sadat Mirenayat M; Abedini A; Kiani A; Eslaminejad A; MohammadReza Hashemian S; Jamaati H; Zali A; Akbar Velayati A; Tabarsi P
    Int Immunopharmacol; 2021 Mar; 92():107329. PubMed ID: 33412395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial.
    Liu P; Huang Z; Yin M; Liu C; Chen X; Pan P; Kuang Y
    Trials; 2020 Dec; 21(1):999. PubMed ID: 33276811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
    Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
    Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lopinavir-ritonavir for COVID-19: A living systematic review.
    Verdugo-Paiva F; Izcovich A; Ragusa M; Rada G
    Medwave; 2020 Jul; 20(6):e7967. PubMed ID: 32678815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial.
    Shi N; Guo L; Liu B; Bian Y; Chen R; Chen S; Chen Y; Chen Y; Cong X; Dong G; Guo J; Hu L; Jiang J; Leng L; Li B; Li D; Li H; Li J; Li L; Liu J; Lu C; Lv W; Miao Q; Qi W; Shi Z; Shi J; Shi H; Tian Y; Wang B; Wang G; Wang J; Wang W; Xian Y; Xie X; Xiong Y; Xu C; Xu M; Yan B; Yang J; Zhang L; Zhou Z; Zhu H; Huang L
    Phytomedicine; 2021 Jan; 81():153367. PubMed ID: 33260064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
    Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does lopinavir measure up in the treatment of COVID-19?
    Doggrell SA
    Expert Opin Investig Drugs; 2020 Aug; 29(8):793-796. PubMed ID: 32475183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
    Liu X; Chen H; Shang Y; Zhu H; Chen G; Chen Y; Liu S; Zhou Y; Huang M; Hong Z; Xia J
    Trials; 2020 Jul; 21(1):622. PubMed ID: 32641091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: A retrospective study in two designated hospitals in Anhui, China.
    Zuo Y; Liu Y; Zhong Q; Zhang K; Xu Y; Wang Z
    J Med Virol; 2020 Nov; 92(11):2666-2674. PubMed ID: 32492211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
    Arabi YM; Gordon AC; Derde LPG; Nichol AD; Murthy S; Beidh FA; Annane D; Swaidan LA; Beane A; Beasley R; Berry LR; Bhimani Z; Bonten MJM; Bradbury CA; Brunkhorst FM; Buxton M; Buzgau A; Cheng A; De Jong M; Detry MA; Duffy EJ; Estcourt LJ; Fitzgerald M; Fowler R; Girard TD; Goligher EC; Goossens H; Haniffa R; Higgins AM; Hills TE; Horvat CM; Huang DT; King AJ; Lamontagne F; Lawler PR; Lewis R; Linstrum K; Litton E; Lorenzi E; Malakouti S; McAuley DF; McGlothlin A; Mcguinness S; McVerry BJ; Montgomery SK; Morpeth SC; Mouncey PR; Orr K; Parke R; Parker JC; Patanwala AE; Rowan KM; Santos MS; Saunders CT; Seymour CW; Shankar-Hari M; Tong SYC; Turgeon AF; Turner AM; Van de Veerdonk FL; Zarychanski R; Green C; Berry S; Marshall JC; McArthur C; Angus DC; Webb SA;
    Intensive Care Med; 2021 Aug; 47(8):867-886. PubMed ID: 34251506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
    Smolders EJ; Te Brake LH; Burger DM
    Antivir Ther; 2020; 25(7):345-347. PubMed ID: 32589165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.
    Ader F;
    Clin Microbiol Infect; 2022 Sep; 28(9):1293-1296. PubMed ID: 35533972
    [No Abstract]   [Full Text] [Related]  

  • 36. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
    Lan X; Shao C; Zeng X; Wu Z; Xu Y
    Int J Clin Pharmacol Ther; 2021 May; 59(5):378-385. PubMed ID: 33624583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: A retrospective matched-pair cohort study.
    Yu C; Zhang Z; Guo Y; Shi J; Pei G; Yao Y; Liao W; Zeng R
    J Med Virol; 2021 Jan; 93(1):472-480. PubMed ID: 32621621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
    Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
    J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
    Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review.
    Hariyanto TI; Kristine E; Jillian Hardi C; Kurniawan A
    Infect Disord Drug Targets; 2021; 21(5):e270421187364. PubMed ID: 33121422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.